Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress nixes expanding FTC powers

This article was originally published in The Tan Sheet

Executive Summary

Congress drops a proposal to dramatically expand the Federal Trade Commission's authorities, much to the relief of the dietary supplement and other industries. Conference committee members agreed June 25 to a version of the Restoring American Financial Stability Act, H.R. 4173, without a provision to allow FTC to adopt regulations via Administrative Procedure Act rulemaking procedures. The Natural Products Association and the Council for Responsible Nutrition lobbied against the provision (1"The Tan Sheet" April 26, 2010). NPA and CRN support enhancing FTC's enforcement capabilities, but say the changes the House proposed were unfair and should not be part of legislation about unrelated issues. "There's nothing about giving FTC any additional powers that had anything to do with Wall Street," said NPA Executive Director and CEO John Gay. "We believe that there needs to be more activity by FTC going after some of the bad actors in the supplement industry," said Mike Greene, CRN's VP of governmental relations

You may also be interested in...

FTC Provision In Finance Reform Bill Could Bite Supplement Firms

Dietary supplement trade groups join a wide swath of industries telling Congress a minor provision of extensive financial services reform legislation would give the Federal Trade Commission nearly unfettered rulemaking authority

Teva Concedes On US Gimoti ANDA, Voiding 180-Day Exclusivity

Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.

Amgen Builds Up Future Launches As Oncology Biosimilars Slide

Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts